This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mesoblast Receives Clearance To Begin First European Trial Of Allogeneic Or 'Off-The-Shelf' Stem Cell Treatment For Heart Attacks

"The preclinical data were very compelling, and formed the basis for this innovative clinical trial," said the study's Principal Investigator, Professor Eric Duckers, M.D., Ph.D., Interventional Cardiologist, Head of Molecular Cardiology & Associate Professor, Thoraxcenter, Erasmus University Hospital in The Netherlands.

"We are excited to be pioneering a novel and minimally invasive clinical approach that has the potential to greatly improve the quality of life for patients suffering acute heart attacks," Professor Duckers added.

The UK's lead investigator, Dr Jonathan Hill, Consultant Interventional Cardiologist at King's College Hospital and King's Health Partners Academic Health Sciences Centre, said: "This stem cell product has the potential to change the medical paradigm for treatment of large heart attacks, and to provide for the first time a validated and effective off-the-shelf therapy for routine use."

Mesoblast Chief Executive Professor Silviu Itescu said the company was delighted to be progressing into a second major clinical indication for its proprietary stem cell product Revascor(TM), which is already well advanced in clinical development for congestive heart failure, with plans to expand its use for chronic refractory angina.

"If the preclinical results are reproduced in this trial, we will have a product that will make a significant impact on the lives of patients after a debilitating heart attack," Professor Itescu added.

Mesoblast has a strategic partnership with United States biopharmaceutical company Cephalon Inc. to commercialize Revascor(TM) for the broad treatment of cardiovascular diseases.

About Mesoblast

Mesoblast Limited (ASX: MSB) is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com

Notes to Editors

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs